ARIAD Pharma (ARIA) Misses Q1 EPS by 2c

ARIAD Pharma (NASDAQ: ARIA) reported Q1 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $27.26 million.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• InspireMD (NSPR) Tops Q2 EPS by 1c